1,020 results match your criteria Expert Review of Clinical Pharmacology [Journal]


Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.

Expert Rev Clin Pharmacol 2019 Apr 12. Epub 2019 Apr 12.

f Formerly Clinical Development , Ablynx NV , Ghent , Belgium.

Introduction: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets. Clinical studies conducted in aTTP patients confirmed the rapid and sustained complete suppression of the vWF activity using an initial intravenous dose of 10 mg, and a maintenance subcutaneous 10 mg daily dosing regimen, with corresponding favorable efficacy and safety profiles. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1607293DOI Listing
April 2019
5 Reads

Reported needs of information resources, research tools, connectivity and infrastructure among African Pharmacological Scientists to improve future patient care and health.

Expert Rev Clin Pharmacol 2019 Apr 9. Epub 2019 Apr 9.

d Division of Clinical Pharmacology, Department of Laboratory Medicine , Karolinska Institutet, Karolinska University Hospital , Huddinge , Stockholm , Sweden .

Introduction: The potentials of Africa for growth and economic transformation through science remains challenging because of existing gaps in knowledge and infrastructure. The Africa Pharmacological Science Gateway project and the Medicines Utilization Research in Africa Group seeks to meet the research needs of African pharmacologists. This study aimed at identifying priority needs that might be met by access to information and tools through e-infrastructure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1605903DOI Listing

Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses.

Expert Rev Clin Pharmacol 2019 Apr 5. Epub 2019 Apr 5.

a Department of Dermatology , Post Graduate Institute of Medical Education and Research Dr. Ram Manohar Lohia Hospital , New Delhi 110001 , India.

Introduction: Recalcitrant dermatophytoses is on the rise. Though myriad factors may contribute to recalcitrance including terbinafine resistance, itraconazole largely remains sensitive and is increasingly prescribed for dermatophytoses. However, there are increasing instances of patients not responding adequately to itraconazole despite low MICs, probably due to issues plaguing the pelletization process, resulting in suboptimal quality of itraconazole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1604218DOI Listing

The role of pharmacogenomics in adverse drug reactions.

Expert Rev Clin Pharmacol 2019 Mar 27. Epub 2019 Mar 27.

a EuroEspes Biomedical Research Center , Institute of Medical Science and Genomic Medicine , 15165 - Bergondo , Corunna , Spain.

Introduction: Adverse drug reactions (ADRs) are a major health concern worldwide. There are multiple causes of ADRs, some of which are preventable. Pharmacogenomics accounts for ≈80% variability in drug efficacy and safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1597706DOI Listing
March 2019
1 Read

Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.

Expert Rev Clin Pharmacol 2019 Mar 23:1-18. Epub 2019 Mar 23.

a Experimental and Clinical Pharmacology Unit , Centro di Riferimento Oncologico di Aviano (CRO), IRCCS , Aviano (PN) , Italy.

Introduction: The introduction of immune checkpoint inhibitors has been lately proposed for the treatment of hepatocellular carcinoma (HCC) with respect to other cancer types. Several immunotherapeutic approaches are now under evaluation for HCC treatment including: i) antibodies acting as immune checkpoint inhibitors; ii) antibodies targeting specific tumor-associated antigens; iii) chimeric antigen receptor redirected T (CAR-T) cells targeting specific tumor-associated antigens; iv) vaccination strategies with tumor-specific epitopes. Areas covered: The review provides a wide description of the clinical trials investigating the efficacy of the main immunotherapeutic approaches proposed for the treatment of patients affected by HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1598859DOI Listing

Pharmacologic Treatment Options for Type 1 Diabetes: What's New?

Expert Rev Clin Pharmacol 2019 Mar 20. Epub 2019 Mar 20.

a Yale Children's Diabetes Program , Yale University School of Medicine , New Haven , CT , USA.

Introduction: The expanding variety of insulins, including biosynthetic human insulin and rapid and long-acting insulin analogs, have dramatically transformed the management of type 1 diabetes (T1D) over the past 25 years. Moreover, increasing interest in the use of novel drugs developed for the treatment of type 2 diabetes (T2D) as adjunctive therapies for T1D remains a work in progress. Areas Covered: We reviewed articles published up to December 2018 in PubMed and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1597705DOI Listing
March 2019
3 Reads

Ocular dysfunctions and toxicities induced by antiepileptic medications: Types, pathogenic mechanisms, and treatment strategies.

Authors:
Sherifa A Hamed

Expert Rev Clin Pharmacol 2019 Apr 20;12(4):309-328. Epub 2019 Mar 20.

a Department of Neurology and Psychiatry , Assiut University Hospital , Assiut , Egypt.

Introduction: Ocular dysfunctions and toxicities induced by antiepileptic drugs (AEDs) are rarely reviewed and not frequently received attention by treating physicians compared to other adverse effects (e.g. endocrinologic, cognitive and metabolic). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1591274DOI Listing
April 2019
8 Reads

How an engineered therapy could replace the need for potentially harmful plasma infusions.

Authors:
Marie Scully

Expert Rev Clin Pharmacol 2019 Apr 4;12(4):289-291. Epub 2019 Mar 4.

a Department of Haematology , UCLH, Cardiometabolic programme- NIHR UCLH/UCL BRC , London , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1588109DOI Listing

Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.

Expert Rev Clin Pharmacol 2019 Apr 11;12(4):299-308. Epub 2019 Mar 11.

b Department of Gynecology & Obstetrics , GD Hospital & Diabetes Institute , Kolkata , India.

Introduction: Heart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While thiazolidinedione class and saxagliptin has shown a significantly increased risk, sodium-glucose linked co-transporter 2 inhibitors (SGLT-2Is) have demonstrated a significant reduction in the risk of hHF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1588110DOI Listing
April 2019
11 Reads

First line of biological drugs in rheumatoid arthritis: a medication persistence analysis.

Expert Rev Clin Pharmacol 2019 Apr 22;12(4):363-370. Epub 2019 Mar 22.

a Department of Social Pharmacy, School of Pharmacy , Federal University of Minas Gerais , Belo Horizonte , Brazil.

Objectives: To evaluate the persistence of biological drugs used as the first line of biological treatment in patients diagnosed with rheumatoid arthritis. The predictors associated with persistence have also been verified.

Methods: We evaluated a historical cohort composed of users of the Brazilian National Health System in the period between 2006 January and 2014 December. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1586533DOI Listing
April 2019
7 Reads

Revefenacin for the treatment of chronic obstructive pulmonary disease.

Expert Rev Clin Pharmacol 2019 Apr 22;12(4):293-298. Epub 2019 Mar 22.

b Department of Pharmaceutical , Central Hospital of Linyi City , Yishui , Shandong , China.

Introduction: Acetylcholine is the predominant parasympathetic neurotransmitter in the airways, and plays a key role in the pathophysiology of chronic obstructive pulmonary disease (COPD). Muscarinic receptors are found in smooth muscle cells and submucosal glands. Binding of acetylcholine to muscarinic receptors could trigger bronchoconstriction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1587292DOI Listing
April 2019
12 Reads

Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.

Expert Rev Clin Pharmacol 2019 Apr 11;12(4):371-378. Epub 2019 Mar 11.

b Department of Hematology , The First Affiliated Hospital of Harbin Medical University , Harbin , China.

Background: Arsenic trioxide (ATO) is widely applied to treat acute promyelocytic leukemia (APL). To elucidate metabolism and toxicity of arsenic, we analyzed time course of arsenic species in red blood cells (RBCs) of APL patients.

Methods: Nine APL patients received ATO (0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1586532DOI Listing

Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.

Expert Rev Clin Pharmacol 2019 Apr 26;12(4):355-361. Epub 2019 Feb 26.

b Department of Paediatric Gastroenterology , Erasmus MC-Sophia Children's Hospital , Rotterdam , The Netherlands.

Introduction: The onset of inflammatory bowel disease (IBD) in children is rising. Current treatment options are based on immunomodulatory therapy. Alternative treatment options are upcoming since they appear to be effective in individual patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1582330DOI Listing
April 2019
3 Reads

Unraveling 'The Cancer Genome Atlas' information on the role of SLC transporters in anticancer drug uptake.

Expert Rev Clin Pharmacol 2019 Apr 26;12(4):329-341. Epub 2019 Feb 26.

a Experimental Hepatology and Drug Targeting (HEVEFARM) , University of Salamanca, IBSAL , Salamanca , Spain.

Introduction: Anticancer chemotherapy often faces the problem of intrinsic or acquired drug refractoriness due in part to efficient mechanisms of defense present or developed, respectively, in cancer cells. Owing to their polarity and/or high molecular weight, many cytostatic agents cannot freely cross the plasma membrane by simple diffusion and hence depend on SLC proteins to enter cancer cells. The downregulation of these transporters and the appearance of either inactivating mutations or aberrant splicing, hamper the possibility of anticancer drugs to interact with their intracellular targets. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1581605DOI Listing
April 2019
6 Reads

Research on medication use in the neonatal intensive care unit.

Expert Rev Clin Pharmacol 2019 Apr 20;12(4):343-353. Epub 2019 Feb 20.

c Division of Clinical Pharmacology, Department of Pediatrics , Children's National Health System , Washington , DC , USA.

Introduction: Research on medication use aims at assessing how much of current pharmacotherapy is rational. In neonates, this is hampered by extensive off-label drug use and limited knowledge. Areas covered: We report on medication use research and have conducted a systematic review of observational studies on medication use to provide an updated overview on characteristics, objectives, methods, and patterns in hospitalized neonates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1580569DOI Listing
April 2019
2 Reads

A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults.

Expert Rev Clin Pharmacol 2019 Mar 8;12(3):219-234. Epub 2019 Feb 8.

b Mental Health Research Center at Eastern State Hospital , University of Kentucky , Lexington , KY , USA.

Introduction: This is a comprehensive review of antipsychotic (AP)-induced dysphagia and its complications: choking and pneumonia. Areas covered: Four PubMed searches were completed in 2018. The limited literature includes: 1) 45 case reports of AP-induced dysphagia with pharmacological mechanisms, 2) a systematic review of APs as a risk factor for dysphagia, 3) reviews suggesting adult patients with intellectual disability (ID) and dementia are prone to dysphagia (APs are a risk factor among multiple others), 4) studies of the increased risk of choking in patients with mental illness (APs are a contributing factor), 5) naturalistic pneumonia studies suggesting that pneumonia may contribute to AP-increased death in dementia, and 6) naturalistic studies suggesting that pneumonia may be a major cause of morbidity and mortality in clozapine patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1577134DOI Listing
March 2019
3 Reads

Hepatitis D - how is the fight against this foe going?

Expert Rev Clin Pharmacol 2019 Mar 6;12(3):169-171. Epub 2019 Feb 6.

a CRC "A. M. and A. Migliavacca" Center for the Study of Liver Disease, Division of Gastroenterology and Hepatology , Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano , Milan , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1577135DOI Listing
March 2019
16 Reads

Switching strategies in the recent era of antiretroviral therapy.

Expert Rev Clin Pharmacol 2019 Mar 13;12(3):235-247. Epub 2019 Feb 13.

a HIV and STI Unit, Infectious Disease Department , IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet , Barcelona , Spain.

Introduction: Although antiretroviral therapy is highly effective, many patients may benefit from switching strategies. Rapid advances in the development of new antiretroviral drugs could enhance the success of these approaches. In this review, we build on a previous review from 2014 and summarize the current options for switching strategies in virologically suppressed HIV-infected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1575728DOI Listing

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.

Expert Rev Clin Pharmacol 2019 Mar 6;12(3):197-218. Epub 2019 Feb 6.

b Servicio de Hematología y Hemoterapia , Hospital Universitari i Politècnic La Fe , Valencia , Spain.

Introduction: Induction chemotherapy based on anthracyclines and cytarabine (Ara-C) combination remains the standard of care for acute myeloid leukemia (AML) patients who are considered candidate for intensive and curative approaches. However, the toxicity of this regimen is high, with disappointing clinical outcomes among the so-called poor-prognosis AML subsets, which generally refer to patients with adverse cytogenetic risk, secondary AML including therapy-related AML, poor-prognosis mutations, especially FLT3-ITD, and relapse/refractory AML. Areas covered: To the best of our knowledge, the role and efficacy of 7 + 3 schedules containing daunorubicin (DNR) and Ara-C for certain types of poor-prognosis AML has not been systematically assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1573668DOI Listing

Mechanism-based pain management in chronic pancreatitis - is it time for a paradigm shift?

Expert Rev Clin Pharmacol 2019 Mar 5;12(3):249-258. Epub 2019 Feb 5.

a Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology , Aalborg University Hospital , Aalborg , Denmark.

Introduction: Pain is the most common symptom in chronic pancreatitis and treatment remains a challenge. Management of visceral pain, in general, is only sparsely documented, and treatment in the clinic is typically based on empirical knowledge from somatic pain conditions. This may be problematic, as many aspects of the neurobiology differ significantly from somatic pain, and organs such as the gut and liver play a major role in tolerability to analgesics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1571409DOI Listing
March 2019
2 Reads

Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Expert Rev Clin Pharmacol 2019 Mar 30;12(3):173-178. Epub 2019 Jan 30.

a Department of Pharmaceutical , Central Hospital of Linyi City , Yishui , Shandong , China.

Introduction: Approximately 3-5% of patients with non-small cell lung cancer (NSCLC)belonged to anaplastic lymphoma kinase (ALK)-positive NSCLC. The treatment drugs of ALK-positive NSCLC mainly included crizotinib, ceritinib, alectinib, and brigatinib. Although these drugs had some effects, most of them were usually easy to develop drug resistance. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1570846DOI Listing
March 2019
19 Reads

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.

Expert Rev Clin Pharmacol 2019 Mar 24;12(3):259-266. Epub 2019 Jan 24.

a Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics , Istituto Nazionale Tumori IRCCS Fondazione G. Pascale , Napoli , Italy.

Introduction: Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard of care for patients with advanced BRAF mutation-positive melanoma. With the currently available combinations of dabrafenib plus trametinib and vemurafenib plus cobimetinib, median progression-free survival (PFS) of over 12 months has been achieved. However, treatment resistance and disease recurrence remain a clinical challenge. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1570847DOI Listing
March 2019
11 Reads

A meta-analysis of naldemedine for the treatment of opioid-induced constipation.

Expert Rev Clin Pharmacol 2019 Feb 24;12(2):121-128. Epub 2019 Jan 24.

a Department of Anesthesiology , the First Hospital of Jilin University , Changchun , China.

Introduction: Opioid-induced constipation (OIC) is a common adverse effect in patients under long-term opioid therapy. Naldemedine is a novel peripherally acting μ-opioid receptor antagonists being developed for the treatment of OIC without affecting central analgesia. This meta-analysis is to assess the current evidence for efficacy and safety of naldemedine for the treatment of OIC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1570845DOI Listing
February 2019
1 Read

Green tobacco sickness: mecamylamine, varenicline, and nicotine vaccine as clinical research tools and potential therapeutics.

Authors:
Lance R McMahon

Expert Rev Clin Pharmacol 2019 Mar 24;12(3):189-195. Epub 2019 Jan 24.

a Department of Pharmacodynamics, College of Pharmacy , University of Florida , Gainesville , FL , USA.

Introduction: Green tobacco sickness occurs from transdermal absorption of chemicals from freshly harvested, green tobacco leaves. Signs and symptoms include nausea, vomiting, headache, and abdominal cramps. Prevalence has shifted from the United States and Europe to China, India, and Brazil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1570844DOI Listing
March 2019
2 Reads

Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.

Authors:
Junyi Yang

Expert Rev Clin Pharmacol 2019 Feb 18;12(2):95-99. Epub 2019 Jan 18.

a Department of Pharmaceutical , Central Hospital of Linyi City , Yishui , Shandong , China.

Introduction: Hereditary transthyretin-mediated amyloidosis is caused by a mutation in transthyretin (TTR) gene resulting in misfolded TTR protein accumulating as amyloid fibrils. Patisiran is a lipid nanoparticle formulation of ribonucleic acid interference (RNAi), which can reduce the production of TTR. Areas covered: In this review, the chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of patisiran were introduced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1567326DOI Listing
February 2019
3 Reads

Future perspectives of the pharmacological management of diabetic dyslipidemia.

Expert Rev Clin Pharmacol 2019 Feb 22;12(2):129-143. Epub 2019 Jan 22.

c Division of Endocrinology , Diabetes and Metabolism University of South Carolina School of Medicine Columbia , South Carolina , SC , USA.

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase subtilisin/kexin type 9) or novel anti-diabetic agents (dipeptidyl peptidase-4 inhibitors (DPP-4is), glucagon like peptide-1 receptor agonist (GLP-1RA), sodium/glucose cotransporter 2 inhibitors (SGLT2is)) or nutraceuticals (berberine, omega 3 fatty acid, red yeast rice) can be used alone or in combination. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1567328DOI Listing
February 2019
16 Reads

Acalabrutinib for adults with mantle cell lymphoma.

Expert Rev Clin Pharmacol 2019 Mar 26;12(3):179-187. Epub 2019 Jan 26.

b Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1568868DOI Listing
March 2019
22 Reads

Novel developments of hepatitis B: treatment goals, agents and monitoring tools.

Expert Rev Clin Pharmacol 2019 Feb 21;12(2):109-120. Epub 2019 Jan 21.

a Department of Medicine , The University of Hong Kong , Hong Kong , Hong Kong.

Introduction: Chronic hepatitis B (CHB) infection causes considerable morbidity and mortality and hence should be a target for global elimination. In recent years, advances have been made in understanding the disease pathophysiology and the relationship to clinical outcome. Novel treatment targets are actively being sought in the hope of improving the treatment outlook. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1567327DOI Listing
February 2019
17 Reads

Guideline recommendations on the pharmacological management of non-specific low back pain in primary care - is there a need to change?

Expert Rev Clin Pharmacol 2019 Feb 16;12(2):145-157. Epub 2019 Jan 16.

c Sydney School of Public Health , The University of Sydney , Sydney , Australia.

Introduction: Analgesic drugs are often prescribed to patients with non-specific low back pain (NSLBP). Recommendations for non-invasive pharmacological management of NSLBP from recent clinical practice guidelines were compared with each other and with the best available evidence on drug efficacy. Areas covered: Recommendations concerning opioids, non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, antidepressants, anticonvulsants and muscle relaxants from national primary care guidelines published within the last 3 years were included in this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1565992DOI Listing
February 2019
2 Reads

Correction.

Authors:

Expert Rev Clin Pharmacol 2019 Feb 29;12(2):ix. Epub 2018 Dec 29.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1560726DOI Listing
February 2019
1 Read

The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.

Expert Rev Clin Pharmacol 2019 Feb 16;12(2):101-108. Epub 2019 Jan 16.

d Department of Surgery The Urban Meyer III and Shelley Meyer Chair for Cancer Research Professor of Surgery, Oncology, and Health Services Management and Policy , The Ohio State University, Wexner Medical Center , Columbus , OH , USA.

Introduction: Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are unique and complex neoplasms, exhibiting a wide spectrum of diverse clinical behaviors. The contemporary management of well-differentiated GEP-NETs is marked by the availability of a wide range of targeted therapies. Areas Covered: For patients with localized or oligometastatic disease, surgical resection remains the preferred approach and is associated with excellent long-term outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1561273DOI Listing
February 2019
2 Reads

Clinical pharmacology in HIV cure research - what impact have we seen?

Expert Rev Clin Pharmacol 2018 Dec 20. Epub 2018 Dec 20.

a Infectious Diseases Unit, DIBIC Luigi Sacco , University of Milan , Milan , Italy .

Introduction Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered The present review assesses the principal pharmacological strategies that have been tested for an HIV cure starting from the in vitro proof of concept and the potential rationale of their in vivo applicability. We evaluated the possible pharmacological procedures employed during the early-stage HIV infection and the possibility of cART-free remission. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1561272DOI Listing
December 2018
13 Reads

Does high LDL-cholesterol cause cardiovascular disease?

Expert Rev Clin Pharmacol 2019 Feb 26;12(2):91. Epub 2018 Dec 26.

c Nutrition and Metabolism, Faculty of Medicine , University of Southampton , Southampton , UK.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1561100DOI Listing
February 2019
9 Reads

Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: Presentations, causes and treatment strategies.

Authors:
Sherifa A Hamed

Expert Rev Clin Pharmacol 2018 Dec 2. Epub 2018 Dec 2.

a Department of Neurology and Psychiatry , Assiut University Hospital , Assiut , Egypt.

Introduction: Uremic syndrome of chronic kidney disease (CKD) is a term used to describe clinical, metabolic and hormonal abnormalities associated with progressive kidney failure. It is a rapidly growing public health problem worldwide. Nervous system complications occur in every patient with uremic syndrome of CKD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1555468DOI Listing
December 2018
4 Reads

The clinical pharmacology of integrase inhibitors.

Expert Rev Clin Pharmacol 2018 Dec 4. Epub 2018 Dec 4.

a The Infectious Diseases Unit, Department of Medical Sciences , The University of Torino, School of Medicine , Ospedale Amedeo di Savoia, Corso Svizzera 164, 10149 Torino , Italy.

Introduction: Treatment of HIV infection has consistently evolved in the last three decades. A steady improvement in efficacy tolerability, safety and practical aspects of treatment intake has made HIV infection much easier to manage over the long term, and in optimal treatment conditions the life expectancy of persons living with HIV infection now approaches the values of the general population. The last category of antiretrovirals to be fully developed for clinical use is the one of strand-transfer integrase inhibitors (INSTIs). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1553615DOI Listing
December 2018
16 Reads

Managing chronic kidney disease in diabetes patients with the latest chemical therapies.

Expert Rev Clin Pharmacol 2018 Dec 3:1-8. Epub 2018 Dec 3.

a College of Pharmaceutical Science , Zhejiang University , Hangzhou , China.

Introduction: During the years, while treatment strategy for diabetes mellitus has improved, the incidence of diabetes worldwide increases continuously. Chronic kidney disease (CKD) is one of the major diabetic microvascular complications, and a primary cause leading to end-stage renal disease (ESRD). The progression to ESRD, affected by hyperglycemia and hypertension, is characterized by microalbuminuria and macroalbuminuria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1552829DOI Listing
December 2018
1 Read

A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs.

Expert Rev Clin Pharmacol 2019 Jan 3;12(1):45-52. Epub 2018 Dec 3.

d North Florida Regional Medical Center, The Cardiac and Vascular Institute , University of Central Florida (Gainesville) , Gainesville , FL , USA.

Introduction: Type 2 diabetes (T2D) is an independent risk factor for heart failure (HF). With concomitant T2D and HF, recent data suggests an incremental risk of cardiovascular death and hospitalization for HF, as compared to patients with HF without T2D. Areas covered: Management of these two diseases has been a challenge for physicians. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1552830DOI Listing
January 2019
5 Reads

From pharmaceuticals to nutraceuticals: bridging disease prevention and management.

Expert Rev Clin Pharmacol 2019 Jan 30;12(1):1-7. Epub 2018 Nov 30.

a Department of Pharmacy , University of Napoli Federico II , Napoli , Italy.

Introduction: Nutraceuticals, up today, do not have a specific definition distinct from those of other food-derived categories, e.g. food supplements, herbal products, pre and probiotics, functional foods, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1552135DOI Listing
January 2019
17 Reads

Intensified antibiotic treatment of tuberculosis meningitis.

Expert Rev Clin Pharmacol 2019 Mar 12;12(3):267-288. Epub 2019 Feb 12.

f Department of Internal Medicine and Radboud Center for Infectious Diseases , Radboud university medical center , Nijmegen , the Netherlands.

Introduction: Meningitis is the most severe manifestation of tuberculosis, resulting in death or disability in over 50% of those affected, with even higher morbidity and mortality among patients with HIV or drug resistance. Antimicrobial treatment of Tuberculous meningitis (TBM) is similar to treatment of pulmonary tuberculosis, although some drugs show poor central nervous system penetration. Therefore, intensification of antibiotic treatment may improve TBM treatment outcomes. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1552831DOI Listing
March 2019
10 Reads

A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

Expert Rev Clin Pharmacol 2018 Nov 22. Epub 2018 Nov 22.

a Division of Early Drug Development for Innovative Therapies , IEO, European Institute of Oncology, IRCCS Milano.

Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifications of the standard treatment in terms of de-escalation by either shortening the duration or giving less resource-demanding regimens and in terms of escalation by either adding a second anti-HER2 agent or extending the duration of HER2-targeted treatment for more than 12 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1552134DOI Listing
November 2018
19 Reads

Mometasone furoate sinus implant - a new targeted approach to treating recurrent nasal polyp disease.

Expert Rev Clin Pharmacol 2018 Nov 20. Epub 2018 Nov 20.

a Feinberg School of Medicine, Department of Otolaryngology - Head and Neck Surgery , Northwestern University , Chicago , IL , USA.

Introduction: Chronic rhinosinusitis (CRS) is a broad heterogeneous inflammatory disorder of the nose and paranasal sinuses, resulting from the dysfunctional interplay between host immunity, defective epithelial barrier, and environmental factors. CRS with nasal polyps (CRSwNP) is considered a more severe clinical phenotype with greater burden of symptoms and higher relapse rate, especially with comorbid asthma or aspirin sensitivity. Available treatment options after endoscopic sinus surgery (ESS) - systemic corticosteroids or revision surgery - have significant risks and limitations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1549485DOI Listing
November 2018
13 Reads

Drug and therapeutics committees in Nigeria: evaluation of scope and functionality.

Expert Rev Clin Pharmacol 2018 Nov 17:1-8. Epub 2018 Nov 17.

j Division of Clinical Pharmacology, Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden.

Introduction: Inappropriate use of medicines remains a problem, with consequences including increasing adverse drug reactions (ADRs) and prolonged hospitalizations. The Essential Medicines List and Drug and Therapeutics Committees (DTCs) are accepted initiatives to promote the rational use of medicines. However, little is known about DTC activities in Nigeria, the most populous African country. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2018.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2018.1549488DOI Listing
November 2018
13 Reads

Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.

Expert Rev Clin Pharmacol 2018 Dec 4;11(12):1209-1218. Epub 2018 Dec 4.

a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Introduction: Psoriasis is a common chronic skin condition that is prevalent worldwide. Despite the numerous treatment options available, discrepancies exist between international guidelines. Areas covered: This review aims to evaluate the current international guidelines for the systemic treatment of psoriasis and psoriatic arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1548277DOI Listing
December 2018
3 Reads

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone.

Expert Rev Clin Pharmacol 2018 Dec 4;11(12):1237-1253. Epub 2018 Dec 4.

e University of Kentucky Mental Health Research Center at Eastern State Hospital , Lexington , KY , USA.

Introduction: This is a combined analysis of therapeutic drug monitoring (TDM) studies of long-acting injectable paliperidone formulations: monthly (PP1M) and three-month (PP3M) injections. Areas covered: Fourteen PP1M articles and one PP3M article were identified. Using the paliperidone concentration/dose (C/D) ratio as a measure of clearance provided a weighted mean of 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1549489DOI Listing
December 2018
5 Reads

Managing antiretroviral therapy in the elderly HIV patient.

Expert Rev Clin Pharmacol 2018 Nov 16:1-11. Epub 2018 Nov 16.

a Modena HIV Metabolic Clinic , Azienda Policlinico-Universitaria di Modena , Modena , Italy.

Introduction: Owing to more effective and less toxic antiretroviral therapy (ART), people living with HIV (PLWH) live longer, a phenomenon expected to grow in the next decades. With advancing age, effectively treated PLWH experience not only a heightened risk for non-infective comorbidities and multimorbidity, but also for geriatric syndromes and frailty. In addition, older adults living with HIV (OALWH) have a higher prevalence of so-called iatrogenic triad described as polypharmacy (PP), potentially inappropriate medication use, and drug-drug interactions. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2018.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2018.1549484DOI Listing
November 2018
15 Reads

Pharmacological treatment of pediatric Gaucher disease.

Expert Rev Clin Pharmacol 2018 Dec 3;11(12):1183-1194. Epub 2018 Dec 3.

b Department of Medicine (Genetics) , University College Dublin , Dublin , Ireland.

Introduction: Gaucher disease (GD) is an autosomal recessive disorder resulting from the deficiency of the lysosomal enzyme glucocerebrosidase (b-glucosidase), associated with varying degrees of visceral, bone and central nervous system pathology, leading to wide phenotypic diversity. Response to therapy and clinical outcomes are very different between the three clinical subtypes - non-neuronopathic, acute neuronopathic, and chronic neuronopathic forms; hence a definitive clinical diagnosis is essential. The availability of two therapeutic options, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1549486DOI Listing
December 2018
15 Reads

Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria.

Expert Rev Clin Pharmacol 2018 Dec 6;11(12):1219-1236. Epub 2018 Dec 6.

a Dipartimento di Scienze della Salute (DISSAL) , University of Genoa , Genoa , Italy.

Introduction: The emergence and diffusion of multidrug-resistant Gram-negative bacteria (MDR-GNB) is an unprecedented threat, with prevalences as high as 10-50% being reported in many countries. Areas covered: In the present review, we discuss the management of infections due to MDR-GNB, focusing in particular on current strategies and novel agents with already available results from phase 3 randomized controlled trials. Expert commentary: Some new drugs, such as ceftolozane/tazobactam, ceftazidime/avibactam, and meropenem/vaborbactam, which have become available in the past months, have increased our chance of improving survival in severe carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae infections; while others, with potent activity against carbapenem-resistant Acinetobacter baumannii which is currently the highest priority regarding the need for novel agents, will become available in the near future. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2018.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2018.1549487DOI Listing
December 2018
16 Reads

Functional and therapeutic potential of mitochondrial SIRT3 deacetylase in disease conditions.

Authors:
Abhinav Kanwal

Expert Rev Clin Pharmacol 2018 Nov 14:1-5. Epub 2018 Nov 14.

a Department of Pharmacology, Manipal College of Pharmaceutical Sciences , Manipal Academy of Higher Education (MAHE) , Manipal , India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1546119DOI Listing
November 2018
1 Read

Controversies in the pharmacological treatment of Graves' disease in children.

Expert Rev Clin Pharmacol 2018 Nov 15;11(11):1113-1121. Epub 2018 Nov 15.

a UOC Pediatria, Department of Human Pathology of Adulthood and Childhood , University of Messina , Messina , Italy.

Introduction: Graves' disease (GD) is a disorder, in which auto-immunity against the thyroid- stimulating hormone (TSH) receptor is the pivotal pathogenetic element. This disease may have different clinical manifestations, the most common being thyrotoxicosis. Treatment of this condition differs according to its etiology, but there is currently no evidence-based therapeutic strategy which is universally adopted in all countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1546576DOI Listing
November 2018
3 Reads